Trial Summary
What is the purpose of this trial?
Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D\&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Integrated Aging Assessment for Action for Cancer Patients (IA3-CP)?
The research highlights the importance of using geriatric assessments to better understand the health status of older cancer patients, which can help tailor treatments to improve outcomes like quality of life and functional independence. These assessments can identify factors beyond age that affect treatment success, suggesting that IA3-CP could be effective in optimizing cancer care for older adults.12345
Is the Aging Assessment Tool for Cancer Patients safe for humans?
The research highlights that older adults with cancer are at increased risk of treatment-related toxicities, but it does not provide specific safety data for the Aging Assessment Tool for Cancer Patients. It suggests that comprehensive assessments may help identify those at risk of adverse outcomes, but no direct safety information for the tool itself is available.26789
How is the IA3-CP treatment different from other treatments for cancer in older patients?
The IA3-CP treatment is unique because it uses a comprehensive geriatric assessment to tailor cancer care specifically for older patients, considering their functional age rather than just their chronological age. This approach helps identify medical, psychosocial, and functional issues, allowing for more personalized and effective treatment plans.1011121314
Research Team
Russell E Glasgow
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for cancer patients aged 65 or older who speak English or Spanish and are attending their initial oncology visit. They must be willing to participate in all study activities. It's open to those with various cancers, including leukemia, multiple myeloma, kidney tumors, breast cancer, Hodgkin's lymphoma, prostate cancer, and bladder cancer.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Integration of geriatric issues, health behaviors, mental health, and social determinants of health into the IA3-CP system
Treatment
Participants receive feedback and care planning based on IA3-CP assessments
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Integrated Aging Assessment for Action for Cancer Patients (IA3-CP) (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
National Cancer Institute (NCI)
Collaborator